| Personalized circulating tumor DNA analysis as a predictive biomarker in solid tumor patients treated with pembrolizumab SV Bratman, SYC Yang, MAJ Iafolla, Z Liu, AR Hansen, PL Bedard, ... Nature Cancer 1 (9), 873-881, 2020 | 321 | 2020 |
| A distinct innate lymphoid cell population regulates tumor-associated T cells SQ Crome, LT Nguyen, S Lopez-Verges, SYC Yang, B Martin, JY Yam, ... Nature medicine 23 (3), 368-375, 2017 | 148 | 2017 |
| Noncoding somatic and inherited single-nucleotide variants converge to promote ESR1 expression in breast cancer SD Bailey, K Desai, KJ Kron, P Mazrooei, NA Sinnott-Armstrong, ... Nature genetics 48 (10), 1260-1266, 2016 | 96 | 2016 |
| Regulatory T cells in ovarian cancer are characterized by a highly activated phenotype distinct from that in melanoma A Toker, LT Nguyen, SC Stone, SYC Yang, SR Katz, PA Shaw, BA Clarke, ... Clinical Cancer Research 24 (22), 5685-5696, 2018 | 95 | 2018 |
| Somatic BRCA1/2 Recovery as a Resistance Mechanism After Exceptional Response to Poly (ADP-ribose) Polymerase Inhibition S Lheureux, JP Bruce, JV Burnier, K Karakasis, PA Shaw, BA Clarke, ... Journal of clinical oncology 35 (11), 1240-1249, 2017 | 93 | 2017 |
| Landscape of genomic alterations in high-grade serous ovarian cancer from exceptional long-and short-term survivors SYC Yang, S Lheureux, K Karakasis, JV Burnier, JP Bruce, DL Clouthier, ... Genome medicine 10, 1-17, 2018 | 83 | 2018 |
| Pan-cancer analysis of longitudinal metastatic tumors reveals genomic alterations and immune landscape dynamics associated with pembrolizumab sensitivity SY Cindy Yang, SC Lien, BX Wang, DL Clouthier, Y Hanna, I Cirlan, ... Nature communications 12 (1), 5137, 2021 | 75 | 2021 |
| SASH1 is a scaffold molecule in endothelial TLR4 signaling SM Dauphinee, A Clayton, A Hussainkhel, C Yang, YJ Park, ME Fuller, ... The Journal of Immunology 191 (2), 892-901, 2013 | 73 | 2013 |
| An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE) DL Clouthier, SC Lien, SYC Yang, LT Nguyen, VSK Manem, D Gray, ... Journal for immunotherapy of cancer 7, 1-12, 2019 | 49 | 2019 |
| Mutations in CIC and IDH1 cooperatively regulate 2-hydroxyglutarate levels and cell clonogenicity S Chittaranjan, S Chan, C Yang, KC Yang, V Chen, A Moradian, M Firme, ... Oncotarget 5 (17), 7960, 2014 | 49 | 2014 |
| Sequence variant discovery in DNA repair genes from radiosensitive and radiotolerant prostate brachytherapy patients TJ Pugh, M Keyes, L Barclay, A Delaney, M Krzywinski, D Thomas, ... Clinical Cancer Research 15 (15), 5008-5016, 2009 | 47 | 2009 |
| Pre-encoded responsiveness to type I interferon in the peripheral immune system defines outcome of PD1 blockade therapy GM Boukhaled, R Gadalla, HJ Elsaesser, D Abd-Rabbo, R Quevedo, ... Nature Immunology 23 (8), 1273-1283, 2022 | 28 | 2022 |
| All is not lost: learning from 9p21 loss in cancer P Spiliopoulou, SYC Yang, JP Bruce, BX Wang, HK Berman, TJ Pugh, ... Trends in Immunology 43 (5), 379-390, 2022 | 18 | 2022 |
| Predicting toxicity and response to pembrolizumab through germline genomic HLA class 1 analysis MAJ Iafolla, C Yang, V Chandran, M Pintilie, Q Li, PL Bedard, A Hansen, ... JNCI cancer spectrum 5 (1), pkaa115, 2021 | 18 | 2021 |
| Centromeric cohesion failure invokes a conserved choreography of chromosomal mis-segregations in pancreatic neuroendocrine tumor R Quevedo, A Spreafico, J Bruce, A Danesh, S El Ghamrasni, A Giesler, ... Genome Medicine 12, 1-15, 2020 | 13 | 2020 |
| Increase in serum choline levels predicts for improved progression-free survival (PFS) in patients with advanced cancers receiving pembrolizumab GA Watson, E Sanz-Garcia, WJ Zhang, ZA Liu, SYC Yang, B Wang, S Liu, ... Journal for ImmunoTherapy of Cancer 10 (6), 2022 | 10 | 2022 |
| Bespoke circulating tumor DNA (ctDNA) analysis as a predictive biomarker in solid tumor patients (pts) treated with single-agent pembrolizumab (P) MAJ Iafolla, C Yang, S Dashner, W Xu, AR Hansen, PL Bedard, ... J Clin Oncol 37 (15_suppl), 2542-2542, 2019 | 7 | 2019 |
| Immunologic and genomic characterization of high grade serous ovarian cancer (HGSOC) in patients (pts) treated with pembrolizumab (Pembro) in the phase II INSPIRE trial. I Colombo, S Lien, C Yang, DL Clouthier, L Bonilla, S Cyriac, JL Ethier, ... Journal of Clinical Oncology 35 (15_suppl), 5581-5581, 2017 | 6 | 2017 |
| Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours A Nabbi, P Beck, A Delaidelli, DA Oldridge, S Sudhaman, K Zhu, ... Genome Medicine 15 (1), 67, 2023 | 4 | 2023 |
| Selinexor for the treatment of recurrent or metastatic salivary gland tumors: Results from the GEMS‐001 clinical trial A Hernando‐Calvo, E Malone, D Day, A Prawira, I Weinreb, SYC Yang, ... Cancer Medicine 12 (20), 20299-20310, 2023 | 3 | 2023 |
Trevor PughUniversity of Toronto; Princess Margaret Cancer Centre; Ontario Institute for Cancer Research在 utoronto.ca 的电子邮件经过验证
